title: A review of AbobotulinumtoxinA (Dysport).
abstract: AbobotulinumtoxinA was approved by the US Food and Drug Administration in 2009 as the second botulinum neurotoxin type A (BoNTA) for use in facial aesthetics. This article provides an overview of abobotulinumtoxinA's applications and indications as well as safety and efficacy data. AbobotulinumtoxinA is generally well tolerated. Adverse events from abobotulinumtoxinA are similar to those reported with other BoNTA products. Clinical applications of the product are also discussed in this article. Information on handling, storage, and dosing is provided.
authors.affiliation: Private practice in New York, New York, USA. lorenc@lorenc.com
authors.forename: Z Paul
authors.initials: ZP
authors.lastname: Lorenc
authors.forename: Jeffrey M
authors.initials: JM
authors.lastname: Kenkel
authors.forename: Steven
authors.initials: S
authors.lastname: Fagien
authors.forename: Haideh
authors.initials: H
authors.lastname: Hirmand
authors.forename: Mark S
authors.initials: MS
authors.lastname: Nestor
authors.forename: Anthony P
authors.initials: AP
authors.lastname: Sclafani
authors.forename: Jonathan M
authors.initials: JM
authors.lastname: Sykes
authors.forename: Heidi A
authors.initials: HA
authors.lastname: Waldorf
mesh_terms: D019274:Botulinum Toxins, Type A / Q000009:adverse effects / Q000627:therapeutic use*; D005145:Face; D006801:Humans; D018377:Neurotransmitter Agents / Q000009:adverse effects / Q000627:therapeutic use*; D012060:Rejuvenation; D016896:Treatment Outcome
chemical_list: D018377:Neurotransmitter Agents; D019274:Botulinum Toxins, Type A; C542869:abobotulinumtoxinA